Centers of Research Translation (CoRT)

研究翻译中心 (CoRT)

• 批准号: 8731620
• 负责人: S Louis Bridges
• 金额: $ 107.57万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-01 至 2017-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8731620
• 关键词: Affect; African American; Allopurinol; Biological Markers; Blood Pressure; Cardiovascular Diseases; Caring; Caucasians; Caucasoid Race; Chronic; Clinic; Clinical Investigator; Colchicine; Collaborations; Discipline; Dose; Environmental Risk Factor; Ethnic Origin; General Population; Genetic; Goals; Gout; Health; Hyperuricemia; Inflammation; Investigation; Lead; Medical; Methodology; Minority; Minority Groups; Pathogenesis; Patients; Pharmacy facility; Population; Protocols documentation; Public Health; Quality of Care; Race; Research Personnel; Research Project Grants; Risk; Role; Serum; Translational Research; Urate; Vascular Diseases; aging population; base; bench to bedside; compare effectiveness; experience; genetic variant; improved; innovation; novel; prevent; programs; racial and ethnic disparities; treatment as usual; virtual; Affect; African American; Allopurinol; Biological Markers; Blood Pressure; Cardiovascular Diseases; Caring; Caucasians; Caucasoid Race; Chronic; Clinic; Clinical Investigator; Colchicine; Collaborations; Discipline; Dose; Environmental Risk Factor; Ethnic Origin; General Population; Genetic; Goals; Gout; Health; Hyperuricemia; Inflammation; Investigation; Lead; Medical; Methodology; Minority; Minority Groups; Pathogenesis; Patients; Pharmacy facility; Population; Protocols documentation; Public Health; Quality of Care; Race; Research Personnel; Research Project Grants; Risk; Role; Serum; Translational Research; Urate; Vascular Diseases; aging population; base; bench to bedside; compare effectiveness; experience; genetic variant; improved; innovation; novel; prevent; programs; racial and ethnic disparities; treatment as usual; virtual

Gout affects ~1 to 2% of the U.S. population. With an aging population, the societal burden of gout will likely grow. The role of genetic factors on gout and hyperuricemia among different races/ethnicities and the mechanisms by which treatment of hyperuricemia may impact vascular disease remain poorly understood. While the causes of hyperuricemia are known, and efficacious treatments for gout are available, there are large gaps in the quality of care of gout patients. These care gaps, the societal impact of gout, and rising concerns about deleterious effects of hyperuricemia make these conditions ideal targets for translational research. Our multi-disciplinary UAB CORT includes 4 research projects and an administrative core focused on the theme of "Gout and Hyperuricemia: from Bench to Bedside to Backyard. Gout, hyperuricemia, and vascular disease are more common among African Americans than Caucasians, yet little is known about genetic and environmental factors associated with increased risk of gout in this minority population. Our four projects are thus further united by a sub-theme of racial/ethnic disparities in gout and hyperuricemia. We will analyze the association of gout and hyperuricemia with cardiovascular disease in African-Americans and define genetic variants and environmental and medical factors underlying hyperuricemia and gout in this minority group (Project 1); characterize biomarkers of inflammation (CRP), vascular disease (endothelial function), and blood pressure changes associated with the ULT allopurinol (Project 2); examine factors associated with suboptimal gout care and factors influencing effective and safer dosing of allopurinol and colchicine in African-Americans and Caucasians (Project 3); and compare the effectiveness of a novel pharmacy-based "virtual" Gout Clinic that includes protocol-driven care to usual care in the treatment of chronic gout (Project 4). The overall goal of our CORT is to improve the health of patients with gout and hyperuricemia by applying scientifically rigorous, state-of-the-art methodology to clinically important questions in translational investigation and to educate clinical investigators through an enrichment program. Drawing on the unique strengths of many UAB Centers, Departments, and Programs, and in collaboration with an experienced team of 20 investigators representing 5 disciplines, our innovative projects hold the promise of significant improvements in our understanding of the pathogenesis of gout, hyperuricemia, and related co-morbid conditions, and may ultimately lead to better ways to predict, treat, or prevent gout and hyperuricemia.

痛风影响约1％至2％的美国人口。随着人口老龄化，痛风的社会负担可能会增长。遗传因素在不同种族/族裔中痛风和高尿酸血症的作用以及高尿酸血症治疗可能影响血管疾病的机制。虽然已知高尿酸血症的原因，并且有有效的痛风治疗方法，但痛风患者的护理质量存在很大的差距。这些护理差距，痛风的社会影响以及对高尿酸血症有害影响的不断上升的关注，使这些疾病成为转化研究的理想目标。我们的多学科UAB Cort包括4个研究项目和一个关注“痛风和高尿液血症的主题：从长凳到床边再到后院。痛风，高尿酸血症和血管疾病在非洲裔美国人中更为普遍，而不是高贵人，但对这个小型群体的风险增加了，因此对遗传和环境因素而言却鲜为人知，因此，我们四个项目的群体是我们的四个项目 - 我们的四个项目是我们四个项目。痛风和高尿液血症的差异。 （项目2）；研究与非裔美国人和高加索人的痛风护理相关的因素以及影响有效和更安全的剂量的因素（项目3）；并比较一个新型的基于药房的“虚拟”痛风诊所的有效性，该诊所在慢性痛风治疗时包括方案驱动的护理对通常的护理（项目4）。我们CORT的总体目标是通过将科学严格的，最先进的方法应用于转化研究中的临床重要问题，并通过富集计划对临床重要的问题进行临床重要问题，从而改善痛风和高尿酸血症患者的健康。利用许多UAB中心，部门和计划的独特优势，并与代表5个学科的20名调查员的经验丰富的团队合作，我们的创新性项目有望有望大大改善我们对痛风，高尿症，相关的共同食物的发病机理的理解，并可能最终导致更好的方法来预测，预测，预防牙齿和高尿液和超级尿液。